<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Neuro-<z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease (NBD) can be categorized clinically as the <z:hpo ids='HP_0011009'>acute</z:hpo> type--characterized by <z:e sem="disease" ids="C0025309" disease_type="Disease or Syndrome" abbrv="">meningoencephalitis</z:e>--and the <z:hpo ids='HP_0011010'>chronic</z:hpo> progressive type- characterized by <z:hpo ids='HP_0003677'>slowly progressive</z:hpo> <z:hpo ids='HP_0000726'>dementia</z:hpo>, <z:hpo ids='HP_0001251'>ataxia</z:hpo>, and <z:hpo ids='HP_0001260'>dysarthria</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We describe a 35-year clinical course of NBD that was characterized by <z:hpo ids='HP_0003677'>slowly progressive</z:hpo> <z:hpo ids='HP_0001251'>ataxia</z:hpo> and <z:hpo ids='HP_0001260'>dysarthria</z:hpo> despite continued <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> treatment </plain></SENT>
<SENT sid="2" pm="."><plain>Because of <z:e sem="disease" ids="C0011168" disease_type="Disease or Syndrome" abbrv="">difficulties in swallowing</z:e>, which interrupted oral <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> therapy, this case was characterized by recurrent manifestations of neurological symptoms and abnormal MRI findings </plain></SENT>
<SENT sid="3" pm="."><plain>Resumption of <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> therapy was effective </plain></SENT>
<SENT sid="4" pm="."><plain>The patient was a 77-year-old woman who had presented with <z:e sem="disease" ids="C0149745" disease_type="Disease or Syndrome" abbrv="">oral ulceration</z:e> and <z:hpo ids='HP_0001260'>dysarthria</z:hpo> at the age of 42 </plain></SENT>
<SENT sid="5" pm="."><plain>She suffered from Entero-<z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease at the age of 52 and was treated with <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> for 7 years </plain></SENT>
<SENT sid="6" pm="."><plain>Oral <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> therapy was resumed at the age of 64, but her neurological deficit slowly progressed and she developed <z:hpo ids='HP_0010550'>paraplegia</z:hpo> with <z:hpo ids='HP_0002015'>dysphagia</z:hpo> and <z:hpo ids='HP_0001260'>dysarthria</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="50858">Corticosteroids</z:chebi> treatment was interrupted when she was 76; one year later, she was hospitalized in a state of <z:hpo ids='HP_0001262'>somnolence</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Brain MRI scans revealed new lesions with <z:chebi fb="0" ids="33375">gadolinium</z:chebi> enhancement </plain></SENT>
<SENT sid="9" pm="."><plain>We diagnosed <z:hpo ids='HP_0011009'>acute</z:hpo> exacerbation of NBD attacks on the basis of positive findings for HLA-B51, protein elevation, and IL-6 in the cerebrospinal fluid </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="50858">Corticosteroid</z:chebi> treatment was effective </plain></SENT>
<SENT sid="11" pm="."><plain>She became alert, and her MRI findings were no longer abnormal </plain></SENT>
<SENT sid="12" pm="."><plain><z:chebi fb="0" ids="50858">Corticosteroids</z:chebi> administration was continued via percutaneous endoscopic gastrostomy </plain></SENT>
<SENT sid="13" pm="."><plain>Our case suggested that even if neurological exacertion is not obvious during the clinical course, immunosuppressive therapies should be continued for patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> NBD to prevent <z:hpo ids='HP_0011009'>acute</z:hpo> aggravation </plain></SENT>
</text></document>